Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257222 | 0.97 | ALDH1A1 (0.47) | ALDH1A1TSHRALOX15HRH3MEN1 | |
| SCHEMBL3035015 | 0.92 | ALDH1A1 (0.47) | ALDH1A1TSHRHRH3MEN1THRB | |
| SCHEMBL6254588 | 0.89 | ALDH1A1 (0.45) | ALDH1A1TSHRHRH3MEN1THRB | |
| SCHEMBL18028838 | 0.87 | ALDH1A1 (0.43) | ALDH1A1TSHRHRH3THRBCES1 | |
| SCHEMBL6257984 | 0.86 | ALDH1A1 (0.47) | ALDH1A1TSHRHRH3MEN1THRB | |
| SCHEMBL9784800 | 0.83 | TSHR (0.50) | ALDH1A1TSHRHRH3MEN1THRB | |
| SCHEMBL28461985 | 0.82 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL9315416 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL20106532 | 0.81 | ALDH1A1 (0.38) | ALDH1A1HRH3MEN1THRBHTT | |
| SCHEMBL20106526 | 0.81 | ALDH1A1 (0.38) | ALDH1A1HRH3MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7709515-B2 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| CN-100532304-C | Method of making and using a point defect free composition and coated products thereof | HEXION SPECIALTY CHEMICALS INC (US) | 2009-08-26 | — | — | CN | disclosed |
| EP-1204626-B1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| CN-1653013-A | Method of making and using a point defect free composition and coated products thereof | BORDEN CHEM INC (US) | 2005-08-10 | — | — | CN | disclosed |
| US-6909014-B2 | Intermediates for the synthesis of ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-6646170-B2 | Hydroxy derivatives; cardiovascular diseases, dyslipidemias, dysproteinemias, glucose metabolism disorders | ESPERION THERAPEUTICS, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ESPERION THERAPEUTICS, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1204626-A4 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030065195-A1 | Ether compounds | ESPERION THERAPEUTICS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-6506799-B1 | Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and | ESPERION THERAPEUTICS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6459003-B1 | ETHER COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, METABOLISM DISORDERS AND CHOLESTEROL DISORDERS | ESPERION THERAPEUTICS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6410802-B1 | ETHERIFICATION IN PRESENCE OF BASE | ESPERION THERAPEUTICS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1204626-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Esperion Therapeutics Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2000059855-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | ALDH1A1 2677/4885TSHR 2878/4885ALOX15 158/4885 |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ECHS1, GPR119, PC | ALDH1A1 1953/4885TSHR 2318/4885ALOX15 143/4885 |
| US-20030065195-A1 | Ether compounds | GPR119, PPARG, PNLIP | ALDH1A1 3016/4885TSHR 2407/4885ALOX15 282/4885 |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | ALDH1A1 2677/4885TSHR 2878/4885ALOX15 158/4885 |
| US-20050119333-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | ALDH1A1 2677/4885TSHR 2878/4885ALOX15 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.